Tofacitinib May Have Beneficial Effect on JIA Patient Growth
A recent study suggests that long-term treatment with tofacitinib may positively influence growth in patients with juvenile idiopathic arthritis (JIA). The analysis showed that patients aged 12 years or younger experienced greater than expected height velocities, while those older than 12 had expected growth rates. Overall, the findings indicate that tofacitinib treatment can lead to normal growth patterns in JIA patients over time.
- ▪The study included 225 patients aged 2 to less than 18 years with JIA who received continuous tofacitinib treatment.
- ▪Height velocities were greater than expected for patients aged 12 years or younger during treatment.
- ▪An increase in height Z score was detected in pubertal patients with a baseline height Z score less than -1.0 after 24 months of treatment.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Patients with juvenile idiopathic arthritis (JIA) who received long-term tofacitinib treatment had height velocities that appeared greater than expected in those aged 12 years or younger and were as expected in those older than 12 years, relative to reference populations.METHODOLOGY:Researchers conducted a post hoc analysis to evaluate the long-term impact of tofacitinib on height and height velocity in patients with JIA.The analysis included 225 patients aged 2 years to less than 18 years with JIA (median age, 13.0 years; 75.1% girls), primarily with polyarticular course JIA, who received continuous tofacitinib treatment across three studies in the JIA development program conducted in 22 countries.Patients received open-label tofacitinib 5 mg twice daily or an equivalent…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
